BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 17568816)

  • 1. PS-341 or a combination of arsenic trioxide and interferon-alpha inhibit growth and induce caspase-dependent apoptosis in KSHV/HHV-8-infected primary effusion lymphoma cells.
    Abou-Merhi R; Khoriaty R; Arnoult D; El Hajj H; Dbouk H; Munier S; El-Sabban ME; Hermine O; Gessain A; de Thé H; Mahieux R; Bazarbachi A
    Leukemia; 2007 Aug; 21(8):1792-801. PubMed ID: 17568816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas.
    An J; Sun Y; Fisher M; Rettig MB
    Leukemia; 2004 Oct; 18(10):1699-704. PubMed ID: 15343345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.
    Strauss SJ; Higginbottom K; Jüliger S; Maharaj L; Allen P; Schenkein D; Lister TA; Joel SP
    Cancer Res; 2007 Mar; 67(6):2783-90. PubMed ID: 17363600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arsenic trioxide induces apoptosis in human T-cell leukemia virus type 1- and type 2-infected cells by a caspase-3-dependent mechanism involving Bcl-2 cleavage.
    Mahieux R; Pise-Masison C; Gessain A; Brady JN; Olivier R; Perret E; Misteli T; Nicot C
    Blood; 2001 Dec; 98(13):3762-9. PubMed ID: 11739184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders.
    Canestraro M; Galimberti S; Savli H; Palumbo GA; Tibullo D; Nagy B; Guerrini F; Piaggi S; Cine N; Metelli MR; Petrini M
    Cancer Genet Cytogenet; 2010 Jun; 199(2):110-20. PubMed ID: 20471514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of HHV-8/KSHV infected primary effusion lymphomas in NOD/SCID mice by azidothymidine and interferon-alpha.
    Wu W; Rochford R; Toomey L; Harrington W; Feuer G
    Leuk Res; 2005 May; 29(5):545-55. PubMed ID: 15755507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro.
    Satou Y; Nosaka K; Koya Y; Yasunaga JI; Toyokuni S; Matsuoka M
    Leukemia; 2004 Aug; 18(8):1357-63. PubMed ID: 15190257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I associated adult T-cell leukemia/lymphoma.
    Nasr R; El-Sabban ME; Karam JA; Dbaibo G; Kfoury Y; Arnulf B; Lepelletier Y; Bex F; de Thé H; Hermine O; Bazarbachi A
    Oncogene; 2005 Jan; 24(3):419-30. PubMed ID: 15543232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
    Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
    Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined proteasome and Bcl-2 inhibition stimulates apoptosis and inhibits growth in EBV-transformed lymphocytes: a potential therapeutic approach to EBV-associated lymphoproliferative diseases.
    Srimatkandada P; Loomis R; Carbone R; Srimatkandada S; Lacy J
    Eur J Haematol; 2008 May; 80(5):407-18. PubMed ID: 18221384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
    Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMillin D; Miller JW; Mitsiades N
    Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4706-19. PubMed ID: 17898295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of apoptosis by combined treatment with differentiation-inducing agents and interferon-alpha in human lung cancer cells.
    Yamamoto-Yamaguchi Y; Okabe-Kado J; Kasukabe T; Honma Y
    Anticancer Res; 2003; 23(3B):2537-47. PubMed ID: 12894538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells.
    Johnson TR; Stone K; Nikrad M; Yeh T; Zong WX; Thompson CB; Nesterov A; Kraft AS
    Oncogene; 2003 Aug; 22(32):4953-63. PubMed ID: 12902978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of heat shock protein 90 inhibitors on apoptosis and viral replication in primary effusion lymphoma cells.
    Higashi C; Saji C; Yamada K; Kagawa H; Ohga R; Taira T; Fujimuro M
    Biol Pharm Bull; 2012; 35(5):725-30. PubMed ID: 22687408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteasome inhibitors induce apoptosis and reduce viral replication in primary effusion lymphoma cells.
    Saji C; Higashi C; Niinaka Y; Yamada K; Noguchi K; Fujimuro M
    Biochem Biophys Res Commun; 2011 Dec; 415(4):573-8. PubMed ID: 22074820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cdelta.
    Yan H; Wang YC; Li D; Wang Y; Liu W; Wu YL; Chen GQ
    Leukemia; 2007 Jul; 21(7):1488-95. PubMed ID: 17495969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies.
    Zhao X; Qiu W; Kung J; Zhao X; Peng X; Yegappan M; Yen-Lieberman B; Hsi ED
    Leuk Res; 2008 Feb; 32(2):275-85. PubMed ID: 17659339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biscoclaurine alkaloid cepharanthine inhibits the growth of primary effusion lymphoma in vitro and in vivo and induces apoptosis via suppression of the NF-kappaB pathway.
    Takahashi-Makise N; Suzu S; Hiyoshi M; Ohsugi T; Katano H; Umezawa K; Okada S
    Int J Cancer; 2009 Sep; 125(6):1464-72. PubMed ID: 19521981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of a TRAIL-mediated suicide program by interferon alpha in primary effusion lymphoma.
    Toomey NL; Deyev VV; Wood C; Boise LH; Scott D; Liu LH; Cabral L; Podack ER; Barber GN; Harrington WJ
    Oncogene; 2001 Oct; 20(48):7029-40. PubMed ID: 11704827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors.
    Zheng B; Georgakis GV; Li Y; Bharti A; McConkey D; Aggarwal BB; Younes A
    Clin Cancer Res; 2004 May; 10(9):3207-15. PubMed ID: 15131062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.